Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
NEXT GENERATION NANOPARTICLE-BASED ANTIBACTERIAL TREATMENT FOR INFECTED WOUNDS (NEXTNANO)

Framework: Horizon Europe — Innovative Europe
Programme: European innovation ecosystems
Theme: Elevating the scalability potential of European business
Destination: Elevating the scalability potential of European business
Action type: Coordination and support actions
Countries involved: Estonia
Call: Women TechEU (HORIZON-EIE-2021-SCALEUP-01, 2021)
Start date: 2022-06-01
End date: 2023-05-31
Duration (months): 12.0
Total project cost (EUR): 107142.86
EU funding (EUR): 75000.0
Participants: 1
Project status: CLOSED

Every 5th person with diabetes develops chronic wounds that are frequently infected by bacteria. In 15−27 % cases bacterial wound infection leads to the gangrene that requires an amputation of the leg. 10 mln of amputations occur annually, showing that existing wound infection management treatments are inefficient. NEXTNANO aims to commercialize a new antibacterial nanotechology developed by our scientists and medical doctors to reduce the number of infection-related amputations by 20%. We showed in animals studies that our first product produced on the basis of this technology, an antibacterial wound dressing, is 8x times better than the current commercial best. Women TechEU grant would support the transition of our technology from the research and development stage to the commercialization stage. For that we have 4 Objectives: 1) To upgrade the commercialization strategy of our company; 2) To conduct the clinical assessment of our first product, antibacterial wound dressing; 3) To establish the quality management system (QMS) in our company and 4) To train participants. The main project results will be the improved commercialization strategy (including new contacts with the stakeholders), collaboration with the EU key opinion leaders and established QMS that will greatly increase the connectivity and competitiveness of our women-led deep-tech startup within innovation ecosystems of the EU. This will lead to more inclusive and gender equal innovation ecosystem in EU, since Estonia is one of the EU inclusiveness target countries and has one of the EU's highest inequalities between the salaries and top positions of women and men according to Eurostat. Not least, NEXTNANO will result in significant impacts: environmental (decreased use of antibiotics), societal (20% less amputations) and economical (10 mln eur revenue by 2026 and new high value-added jobs for 15 persons such as scientists, medical doctors, engineers and sales managers).
Unravelling the potential of LysM-domain proteins to awaken silent secondary metabolites genes in predatory bacteria through predator-prey interactions. (LYSM)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-09-01
End date: 2025-08-31
Duration (months): 24.0
Total project cost (EUR): 165312.96
EU funding (EUR): 165312.96
Participants: 1
Project status: CLOSED

As a microbiologist with an expertise based on the study of the genetic response of microorganisms to their environment and other microorganisms, with a strong background in myxobacterial biology, I will study the induction of new antibiotic compounds in predator-prey co-cultures through the LYSM project. A transcriptome analysis of the predator bacterium Myxococcus xanthus in such conditions has revealed the induction of five genes coding for proteins with peptidoglycan-binding LysM domains together with several gene clusters involved in the production of secondary metabolites. The LYSM project will be carried out at the Department of Microbiology of the Universidad de Granada (UGR) under the supervision of Prof. José Muñoz Dorado. Their current line of research in bacterial predation and the experience I acquired throughout my international post-doctoral stages will create a strong synergy where we will achieve greater advances than we would separately. His research group counts with several experts in myxobacteria, bacterial predation, and transcriptional regulation, and an excellent network of international collaborators, that will contribute to the success of this project. This research project aims to discover mechanisms to “awaken” silent new secondary metabolites genes of M. xanthus through predator-prey interaction focusing on the role of peptidoglycan-binding proteins during predation.

Keywords: myxobacteria,bacterial predation,signalling,regulation,soil bacteria,lysm,peptidoglycan,secondary metabolites,antibiotics
Super-resolution microscopy for immune checkpoint inhibitors diagnostics (NANODIAGNOSTIC)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Netherlands
Call: ERC PROOF OF CONCEPT GRANTS2 (ERC-2022-POC2, 2022)
Start date: 2022-12-01
End date: 2024-05-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

In the last decade, super-resolution microscopy techniques have emerged as powerful quantitative tools for biology. They have capabilities to visualize single molecules at the nanoscale opening the door to study biological processes at a level not accessible before. In the ERC StG NANOSTORM we showed the potential of these techniques providing new fundamental knowledge on the mechanism and design of new targeted therapies. However, some of the methods we developed have the potential to be translated into applied clinical diagnostic tools. In NANODIAGNOSTIC, we would offer a proof-of-concept of the application of super resolution microscopy and single-molecule imaging for cancer diagnostic, with a focus on patients stratification for immunotherapy. Novel advances in immunotherapies have brought the development of immune checkpoint inhibitors (ICI) that re-activate the immune system against the tumor. Despite the high success of these therapies there is one main challenge: they are only effective on a limited portion of patients and current diagnostic approaches are not capable of stratifying patient successfully. NANODIAGNOSTIC will translate advance optical methods from an academic setting to the clinic and holds a great potential to provide new diagnostic methods to improve the outcome of immunotherapy.
Greenhouses as Vital Landscapes: Sustainability, Relationality, and the Future of Food (VITALGREENHOUSE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: The Soci al World and Its Interactions
Panel description: Sociology, social psychology, education  sciences , communication  studies
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-08-01
End date: 2029-07-31
Duration (months): 60.0
Total project cost (EUR): 1499964.0
EU funding (EUR): 1499964.0
Participants: 1
Project status: SIGNED

Greenhouses play a crucial role in Europe, ensuring the production of affordable vegetables, but they are under great pressure to change. The EU is encouraging consumers to move towards a plant-based diet, necessitating an increase in horticultural productivity. Simultaneously, the UN’s 2030 Sustainable Development Goals include reducing land degradation and biodiversity loss. Such pressures – including requirements to reduce chemical use in the Netherlands and water use in Spain, and social unrest about the exploitation of migrant workers – challenge the industrial model of production. Using ethnographic methods, VITALGREENHOUSE will examine how greenhouse growers, workers, scientists, and environmental community groups are experimenting with sustainability. In Spain and the Netherlands, both leaders in intensive greenhouse use, our team will study how different versions of sustainability are performed in the various and often competing practices of growing food, handling multispecies relations, and addressing workers’ rights. The work is divided into four subprojects: (1) studying the multispecies relations of growers, pickers, and other non-human laborers such as pollinator bees, (2) investigating how growers and workers are adapting to or resisting ‘climate-intelligent agriculture’, a recent iteration of sustainability, (3) examining how greenhouses spark and sustain labour mobilities, creating novel ways of belonging forged through working in the greenhouse, and (4) historicising and contextualising current sustainability practices in the European greenhouse complex. VITALGREENHOUSE will develop an innovative analytical framework that conceives of sustainability as a relational practice and theorises greenhouses as a vital landscapes. Combining political ecology, science and technology studies, and decolonial thought, VITALGREENHOUSE will produce a new understanding of sustainability for environmental anthropology.

Keywords: greenhouses sustainability agriculture multispecies relations digital transitions labour plantationocene environmental anthropology future of food
Self-interpretability of human cognition: How reportable knowledge emerges in learning (REPORT-IT)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Netherlands
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-08-01
End date: 2026-07-31
Duration (months): 24.0
Total project cost (EUR): 203464.32
EU funding (EUR): 203464.32
Participants: 1
Project status: SIGNED

Current artificial intelligence (AI) surpasses human-level performance in a vast range of tasks. However, its decisional processes are opaque, referred to as the AI interpretability problem. Humans, on the other hand, can verbally describe their decisional processes and strategies. The accuracy of these reports varies, especially in complex environments. Yet, people often come up with reasonably accurate explanations for their decisions, thereby allowing knowledge transfer in society. However, the mechanisms of accurate verbal report generation remain unclear. Therefore, the main research objective of the REPORT-IT project is to study how humans generate adequate reportable knowledge during learning through experience. Inspired by the recent findings from research on metacognition (i.e., insight into one's own cognition) and cognition-emotion interaction, I will test the novel hypothesis that metacognition and learning-related affect support the emergence of reportable knowledge. In two experiments modeling complex learning environments (implicit category learning and probabilistic reward learning tasks), I will track the development of metacognition, affect, and reportable knowledge over time. This will allow me to evaluate the temporal relationships between these components and predict the emergence of reportable knowledge. In the final step of the project, I will study the behavior of deep neural networks (DNNs) in the exact same tasks and test whether DNNs can generate temporal patterns of metacognition and affect, as observed in humans. Thereby, the REPORT-IT project combines my expertise in implicit learning and affective science with expertise in neuroscience of consciousness and DNNs at the host institute (University of Amsterdam). This way, REPORT-IT will contribute to understanding how people generate reportable knowledge and, at the same time, provide new approaches for explainable AI.

Keywords: implicit learning,consciousness,category learning,explicit learning,reward,affect,pupillometry,explainable ai
New encryption standard with true Random Number Generator (BARN)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Poland
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

RANDAEMON is developing an innovative, non-numerical, entropy-based, and quantum-resistant encryption method that will fulfil the growing need for an efficient, convenient-to-use, computationally friendly, and very hard-to-break cryptographic cipher, and a new type of hardware, a true Quantum Random Number Generator (tQRNG), as the source of random bits. Using the tQRNG, the company created and tested a new, disruptive class of ciphers named BARN. The goal of the EIC project is to develop two practical devices: an inexpensive integrated circuit including tQRNG and BARN algorithm, and a high- throughput tQRNG to be used for BARN encryption in cloud servers and other similar applications.

Keywords: post quantum encryption,true random number generation
Aggression reversal: A new oral therapy to redefine cancer treatment (ARCTIC)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: United Kingdom
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 36.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Celex Oncology Innovations Ltd. seeks EIC Accelerator funding to scale up its pioneering therapeutic approach to reverse cancer aggressiveness. Unlike traditional treatments that focus on eliminating tumour cells, often with severe side effects, Celex’s unique approach targeting voltage-gated sodium channels (VGSC) aims to alter the cellular mechanisms that drive cancer invasiveness and metastasis, offering a potentially transformative solution with a high tolerability profile for long-term use. Celex’s lead candidate, CL-S03, is a refined version of the FDA-approved cardiovascular drug ranolazine. EIC support will enable CL-S03 to enter a phase II proof-of-concept trial for triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype lacking effective long-term treatments. Celex holds 13 patents (with 18 pending) and is strategically positioned to compete in the oncology market, gaining interest from leading pharma companies. EIC funding will be critical to demonstrate CL-S03’s efficacy in reversing tumour aggressiveness in TNBC patients, a key milestone to attract larger investments and strategic partnerships for subsequent clinical stages, regulatory approval and commercialization. Celex’s innovative approach has potential applications in over 20 solid tumour types beyond TNBC. The investment aligns with the EU's sustainability and health goals, as it promises to reduce healthcare costs and environmental waste associated with metastatic cancer care. With its unique approach, Celex aims to lead a paradigm shift in cancer treatment, enhancing survival and quality of life for patients worldwide.

Keywords: cancer treatment,clinical development,breast cancer
Human Milk Lactoferrin by Precision Fermentation (HuMiLAF)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Portugal,Belgium
Call: Food from precision fermentation and algae (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-05-01
End date: 2027-04-30
Duration (months): 24.0
Total project cost (EUR): 3571427.14
EU funding (EUR): 2499999.0
Participants: 2
Project status: SIGNED

Precision fermentation presents a transformative solution for today's food system by reducing reliance on animal proteins, offering a sustainable and scalable method for producing specialty proteins. PFx Biotech leverages this innovative technology to produce human milk proteins (HMPs) structurally and functionally identical to those found in human breast milk. This method addresses environmental concerns and ensures higher purity and cost-effectiveness. Proteins like lactoferrin, α-lactalbumin, osteopontin, and immunoglobulins are found in low quantities in cow milk, necessitating the processing of large volumes (e.g., 50 L of milk for 1 g of lactoferrin) and leading to high costs and carbon emissions (50 kg CO2eq). These cow milk-derived proteins also differ by up to 40% in amino acid sequence from their human counterparts, impacting their bioactivity, digestibility, health benefits, and allergenic potential. The infant formula industry is increasingly driven to replicate the composition and bioactivity of human breast milk, but traditional formulas, which use cow milk proteins, fall short due to these structural and functional differences. There is a growing demand for more accurate mimics of human milk to improve infant health outcomes and reduce risks associated with obesity and allergies. The HuMiLAF project aims to scale up the production of human milk lactoferrin (hLF) to a pre-industrial scale, validating its properties and testing its applications. This includes using hLF alone and in micro-and co-encapsulated forms with human milk oligosaccharides (HMOs) and specific probiotic strains in two key products: infant formula and immunity shots. Business objectives include securing regulatory approvals, signing agreements with major customers, and advancing the project to commercialization. This project not only addresses a critical gap in infant nutrition but also positions PFx at the forefront of sustainable and innovative protein production.

Keywords: precision fermentation,human milk proteins,infant nutrition,human milk lactoferrin hlf,strain engineering,non coding sequences,mrna stability,micro and co encapsulation
Cell type-Specific Disease Resistance Against Vascular Xanthomonas Plant Pathogens (XANTHORESIST)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Biotechnology and Biosystems E ngineering
Panel description: Biotechnology using all organisms , biotechnology for environment  and food applications, applied plant and animal sciences , bioengineering and synthetic biology , biomass and biofuels , biohazards
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2025-12-01
End date: 2030-11-30
Duration (months): 60.0
Total project cost (EUR): 1843713.0
EU funding (EUR): 1843713.0
Participants: 1
Project status: SIGNED

Plants restrict entry of pathogens through physical barriers, and via Plants restrict the entry of pathogens through physical barriers and an innate immune system that recognizes pathogenic activity and initiates immune responses to halt the infection. As pathogens employ distinct infection strategies to invade plant tissues, immune responses are not uniform but rather specific for different cell and tissue types. This highlights the need to challenge the current concept of plant immunity and expand it towards a tissue-specific perspective. Vascular pathogens belonging to the bacterial genera Xanthomonas and Clavibacter exploit hydathodes –small multicellular organs at the leaf margin, which extrude xylem sap and are directly connected to the vasculature– as entry point into the plant. Currently, we have little understanding of the immune mechanisms in hydathodes. To address this knowledge gap and overcome technical challenges of studying molecular processes in localized and low abundant hydathode tissue, I propose an ambitious and timely project using state-of-the-art approaches: 1) My goal is to identify elicitors, which are perceived by receptors in hydathodes, triggering immunity by using activity-guided screening of pathogen extracts and mass spectrometry. 2) I aim to isolate and characterise hydathode-inhabiting commensal microbes that play a role in plant protection by, amongst others, laser-microdissection of hydathode tissue and (spatial) microbiota profiling. 3) To dissect cell-specific responses towards pathogens and commensals and to identify hydathode-specific immune pathways, recently available single nucleus RNA sequencing combined with live-cell imaging of fluorescent reporters will be applied. Overall, hydathodes are a unique system to study both tissue-specificity of plant immunity and microbiota-mediated protection. Hence, this project will contribute to a comprehensive view of plant immunity and opens a path to novel plant protection strategies.

Keywords: plant immune signalling,tissue specific immunity,vascular plant pathogens
CREATING AND MANAGING A PIPELINE OF H2020 PROJECTS FOR THE INNOVATION FUND ON CCUS (LEADS)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Cross-sectoral solutions for the climate transition
Action type: Coordination and support actions
Countries involved: Italy,Belgium,Netherlands,Germany,Norway,Greece
Call: Support for the deployment of R&I results for climate mitigation. Synergies with the ETS Innovation Fund (HORIZON-CL5-2023-D2-01, 2023)
Start date: 2024-01-01
End date: 2026-12-31
Duration (months): 36.0
Total project cost (EUR): 1152449.44
EU funding (EUR): 933139.93
Participants: 7
Project status: SIGNED

Carbon capture, use and storage (CCUS) has been recently recognised as a key technology to reduce carbon emissions, especially in hard-to-abate sectors, and significantly contribute to EU carbon neutrality targets for 2030 and 2050. Accelerating the upscaling and subsequent market introduction of CCUS research results and technologies is becoming thus increasingly urgent. The Horizon 2020 Programme (H2020) has contributed to the development of innovative technologies, including CCUS. The Innovation Fund Programme (IF) on the other hand, focuses on commercial demonstration of innovative low-carbon technologies. The transition from mature H2020 projects to the IF is a logical pipeline along the TRL line. Synergies between these and other EU funding programmes can contribute substantially to overcome the hurdles and de-risk large scale investments in first-of-a-kind CCUS flagship projects, but still much remains to be done in accelerating go-to-market strategies for publicly funded innovations. LEADS aims at bridging the gap from research to deployment for CCUS projects in Europe by building an innovation pipeline of promising H2020/HEU projects and supporting project owners to overcome the main bottlenecks and reach final investment decision. Building on their outstanding experience in innovation and EU programmes, as well as leveraging on their strong EU networks, LEADS partners will implement a well-designed methodology and set of measures to assess and select the most promising H2020 projects, coach them and enable them to apply to IF. LEADS methodology will be tested with six H2020 CCUS project cases. A set of reusable IF tools will be created and made available to CCUS stakeholders. Synergy mechanisms between H2020 and IF will be also created by aligning the CCUS up-scaling potential with IF targets. At LEADS project end, at least three H2020 projects are expected to have completed the full LEADS cycle and have submitted a full IF application.

Keywords: ccus,h2020,innovation fund,synergies,innovation pipeline,research to deployment